AstraZeneca PLC (AZN)vsDoorDash, Inc. Class A Common Stock (DASH)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
DASH
DoorDash, Inc. Class A Common Stock
$152.92
-1.17%
CONSUMER CYCLICAL · Cap: $67.22B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 328% more annual revenue ($58.74B vs $13.72B). AZN leads profitability with a 17.4% profit margin vs 6.8%. AZN appears more attractively valued with a PEG of 1.50. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
DASH
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
-75.2%
Fair Value
$100.15
Current Price
$152.92
$52.77 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 37.7% year-over-year
Large-cap with strong market position
Earnings expanding 47.7% YoY
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Grey zone — moderate risk
6.8% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : DASH
The strongest argument for DASH centers on Revenue Growth, Market Cap, EPS Growth. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : DASH
The primary concerns for DASH are PEG Ratio, Altman Z-Score, Profit Margin. A P/E of 72.3x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a value stock while DASH is a hypergrowth play — different risk/reward profiles.
DASH carries more volatility with a beta of 1.90 — expect wider price swings.
DASH is growing revenue faster at 37.7% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (66/100 vs 59/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
DoorDash, Inc. Class A Common Stock
CONSUMER CYCLICAL · INTERNET RETAIL · USA
DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?